

## Rubella Antibody Screening

### **Effective April 24, 2023, CLH will replace Rubella Antibody Total with the Rubella IgG Antibody Test.**

Rubella is a contagious viral illness, also known as German Measles, which prior to vaccination, was responsible for a significant number of fetal losses and congenital abnormalities.<sup>1</sup> Rubella is an exanthematous (skin eruption) illness characterized by non-specific signs and symptoms including transient erythematous and sometimes pruritic rash, postauricular or suboccipital lymphadenopathy, arthralgia, and low-grade fever.<sup>2</sup> Among adults infected with Rubella, the most important consequences are the miscarriages, stillbirths, fetal anomalies, and therapeutic abortions that result when Rubella infection occurs during early pregnancy, especially during the first trimester.<sup>3</sup>

Clinical Labs of Hawaii (CLH) is pleased to announce the transition from Rubella Antibody Total to the Rubella IgG Antibody test by multiplex flow immunoassay. Both tests have been available for some time now but the Rubella IgG antibody test offers a more comprehensive measurement with a more valuable interpretation on immunity status.

This transition will affect all panels including the Obstetric Panel which will now consist of a Complete Blood Count with Differential, RPR with Reflex to Titer, Hepatitis B Surface Antigen, and the Rubella IgG Antibody.

Rubella IgG Antibody							
Test Code	RBGG (4820)						
Ordering Recommendation	For the qualitative detection of IgG antibodies to Rubella.						
Specimen Collection	1.0 ml serum SST or Red top						
Stability after collection	7 days refrigerated; freeze if not tested within 7 days						
Performed at	Heights						
Turn-around Time	Reports in 1-2 days (performed daily)						
Results	Qualitative with interpretation of numeric value						
Reference Range	<table border="0"> <tr> <td>&lt;=0.7 AI</td> <td>Negative</td> </tr> <tr> <td>0.8 – 0.9 AI</td> <td>Equivocal</td> </tr> <tr> <td>&gt;=1.0 AI</td> <td>Positive</td> </tr> </table>	<=0.7 AI	Negative	0.8 – 0.9 AI	Equivocal	>=1.0 AI	Positive
<=0.7 AI	Negative						
0.8 – 0.9 AI	Equivocal						
>=1.0 AI	Positive						
Methodology	Multiplex Flow Immunoassay						
CPT Codes	86762						

#### References:

1. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable disease. [Updated: Jun 2020; Accessed: Mar 2021].
2. Healthcare Personnel Vaccination Recommendations, Immunization Action Coalition, Item #P2017, July 2008.
3. Centers for Disease Control and Prevention. Measles, Mumps, and Rubella- Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1998;47 (No. RR-8).

If you have any questions, please contact our Client Services Department at 808-677-7998 (Oahu) or 1-866-281-6816 (toll-free).

***Thank you for choosing Clinical Labs of Hawaii.***